A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma

Grants and Contracts Details

StatusActive
Effective start/end date12/11/19 → 1/3/26

Funding

  • Rakuten Medical Incorporated: $176,190.00